Vasculitides: Drug Therapy

Therapeutic target

  • Risk reduction or prevention of complications.

Therapy recommendations

Below are treatment recommendations for the most common vasculitides.

Note: The German Society of Rheumatology (DGRh) has advocated the use of the monoclonal antibody rituximab (RTX) in ANCA-associated vasculitides (AAV). Accordingly, rituximab would be an alternative to cyclophosphamide (see below) the current standard of care for AAV.

For more detailed disease-related therapy recommendations, see the corresponding disease.